Alchemix: A novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer

Molecular Cancer Therapeutics

Volumn 2, Issue 7, 2003, Pages 607-610

  Pors, Klaus ^a   Paniwnyk, Zennia ^b   Teesdale Spittle, Paul ^b,e   Plumb, Jane A ^c   Willmore, Elaine ^d   Austin, Caroline A ^d   Patterson, Laurence H ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALCHEMIX; ALKYLATING AGENT; ANTHRACYCLINE; ANTHRAQUINONE DERIVATIVE; CISPLATIN; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; TUMOR ANTIGEN;

ANIMAL; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; DNA REPAIR; DRUG RESISTANCE; FEMALE; HUMAN; IN VITRO STUDY; METABOLISM; MOUSE; NUDE MOUSE; OVARY TUMOR;

ANIMALS; ANTHRACYCLINES; ANTHRAQUINONES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; CISPLATIN; DNA; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 1642341184     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Berger, J. M., and Wang, J. C. Recent developments in DNA topoisomerase II structure and mechanism. Curr. Opin. Struct. Biol., 6: 84-90, 1996. (Pubitemid 26073948)
2. Nitiss, J. L., and Wang, J. C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol., 50: 1095-102, 1996. (Pubitemid 26384847)
3. Faulds, D., Balfour, J. A., Chrisp, P., and Langtry, H. D. Mitoxantrone, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs, 41: 400-449, 1991. (Pubitemid 21920736)
4. Baguley, B. C. DNA intercalating anti-tumour agents. Anti-Cancer Drug Des., 6: 1-35, 1991.
5. Fox, M. E., and Smith, P. J. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumour DNA intercalators mAMSA and mitoxantrone. Cancer Res., 50: 5813-5818, 1990. (Pubitemid 20331382)
6. Giaccone G. Topoisomerase genes and resistance to topoisomerase inhibitors. In: H. M. Pinedo and G. Giaccone (eds.), Drug Resistance in the Treatment of Cancer, pp. 132-177. Cambridge: University Press UK, 1998.
7. Strathdee, G., MacKeen, M. J., Illand, M., and Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, 18: 2335-2341, 1999. (Pubitemid 29192710)
8. Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., Borts, R. H., and Brown, R. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr. Biol., 9: 51-54, 1999. (Pubitemid 29045795)
9. Workman, P., Balmain, A., Hickman, J. A., McNally, N. J., Mitchison, N. A., Pierrepoint, C. G., Raymond, R., Rowlatt, C., Stephens, T. C., and Wallace, J. UKCCR guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer, 58: 109, 1988.
10. Willmore, E., Frank, A. J., Padget, K., Tilby, M. J., and Austin, C. A. Etoposide targets topoisomerase IIα and IIβ in leukaemic cells: isoformspecific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique. Mol. Pharmacol., 54: 78-85, 1998. (Pubitemid 28337589)
11. Piccart, M. J., Lamb, H., and Vermorken, J. B. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann. Oncol., 12: 1195-203, 2001. (Pubitemid 32994741)
12. Ueda, K., Yoshida, A., and Amachi, T. Recent progress in P-glycoprotein research. Anti-Cancer Drug Des., 14: 115-121, 1999. (Pubitemid 29292308)
13. O'Brien, M. L., and Tew, K. D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer, 32A: 967-978, 1996.
14. Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., and Anthoney, D. A. HMLH1 Expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997. (Pubitemid 27348095)
15. Li, Q. D., Tsang, B., Bostick-Bruton, F., and Reed, E. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem. Pharmacol., 57: 347-353, 1999. (Pubitemid 29065282)
16. Akiyama S-I., Chen Z-S., Sumizawa, T., and Furukawa, T. Resistance to cisplatin. Anti-Cancer Drug Des., 14: 143-151, 1999. (Pubitemid 29292311)
17. Parker, R. J., Eastman, A., Bostick-Bruton, F., and Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Investig., 87: 772-777, 1991.
18. Woessner R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2: 209-214, 1991.
19. Patterson, L. H., Paniwnyk, Z., Pors, K., Teesdale-Spittle, P. H., Hartley, J. A., and Plumb, J. A novel alkylating anthraquinone that is effective against resistant ovarian cancer cells. Proc. Am. Assoc. Cancer Res., 44: 2701, 2000.
20. Fedier, A., Schwarz, V. A., Walt, H., Carpini, R. D., Haller, U., and Fink, D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int. J. Cancer, 93: 571-576, 2001. (Pubitemid 32701417)